Cyclophosphamide for Scleroderma Lung Disease

Clinically significant interstitial lung disease affects patients with systemic sclerosis (scleroderma) and is a cause of morbidity and mortality in approximately 40 percent of these patients. 1 Management of this condition remains difficult and controversial. 2 , 3 In this issue of the Journal, Tas...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The New England journal of medicine 2006-06, Vol.354 (25), p.2707-2709
Hauptverfasser:	Martinez, Fernando J, McCune, W. Joseph
Format:	Artikel
Sprache:	eng
Schlagworte:	Autoimmune Diseases - drug therapy Cyclophosphamide - adverse effects Cyclophosphamide - therapeutic use Female Humans Immunosuppressive Agents - therapeutic use Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - immunology Neoplasms - chemically induced Primary Ovarian Insufficiency - chemically induced Scleroderma, Systemic - drug therapy Scleroderma, Systemic - immunology Urinary Bladder Diseases - chemically induced Vital Capacity - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!